相关实验视频
Updated: Jun 23, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
在接受常规护理的2型糖尿病患者中,坚持和持续服用新型降血糖药物
Daniel V O'Hara1, Roemer J Janse2, Edouard L Fu3
1NHMRC Clinical Trials Centre, University of Sydney, Sydney Australia; Royal North Shore Hospital Renal Department, Sydney, Australia.
Diabetes research and clinical practice
|June 14, 2024
概括
与二二基酶-4抑制剂 (DPP4i) 相比,-葡萄糖携带载体-2抑制剂 (SGLT2i) 和葡萄糖类-1受体激动剂 (GLP1-RA) 的和持久性更高. 更好地遵守规则的预测因素包括老年和更好的健康指标.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 现实世界的证据.
背景情况:
- 糖尿病管理依赖于有效的药物坚持和坚持.
- -葡萄糖携带载体-2 抑制剂 (SGLT2i),类似葡萄糖素的-1 受体激动剂 (GLP1-RA) 和二乙酶-4 抑制剂 (DPP4i) 是关键的抗糖尿病药物.
- 了解现实世界的坚持和坚持对于优化治疗结果至关重要.
研究的目的:
- 在日常护理环境中评估和比较SGLT2i,GLP1-RA和DPP4i的坚持和持久率.
- 确定这些抗糖尿病药物的使用者之间不坚持和不持续的预测因素.
主要方法:
- 来自瑞典斯德哥尔摩 (2015-2020年) 的医疗保健数据的回顾性分析.
- 包括SGLT2i,GLP1-RA和/或DPP4i的新用户.
- 坚持性定义为≥80%的覆盖日,持久性定义为没有治疗间隔≥60天.
主要成果:
- 超过2.8年的中位数随访,SGLT2i和GLP1-RA显示出比DPP4i更高的坚持和持久性.
- 坚持率:SGLT2i (57%),GLP1-RA (54%),DPP4i (53%). 这是一个很好的例子. 持久率:SGLT2i (50%),GLP1-RA (49%),DPP4i (44%). 这两种类型的药物都存在.
- 年龄较大,有高血压史,非糖尿病药物使用率较高,功能较好和高等教育预测了更好的坚持. 妇女对SGLT2i和GLP1-RA的坚持更差.
结论:
- 与DPP4i相比,SGLT2i和GLP1-RA在现实临床实践中表现出更高的坚持和持久性.
- 确定预后因素可以指导干预措施,以提高这些重要糖尿病治疗的吸收和有效性.
- 进一步的研究可以完善实施策略,以改善患者的治疗结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
257
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
257
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181

